Effect of increasing doses of vitamin D on bone mineral density and serum N-terminal telopeptide in elderly women

a randomized controlled trial

L. M. Smith, John Christopher G. Gallagher, M. Kaufmann, G. Jones

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Background: There are few controlled studies of the effect of different doses of vitamin D3 on bone mineral density (BMD). Objectives: We conducted a randomized placebo-controlled trial of increasing doses of vitamin D3 in 163 Caucasian and 31 African American women with serum 25-hydroxyvitamin D (25OHD) ≤50 nmol/L. This is an analysis of secondary outcome BMD to see if there is an association between percent change in BMD and dose of vitamin D3. Methods: Participants were randomly assigned to placebo, vitamin D3 400, 800, 1600, 2400, 3200, 4000, or 4800 IU/day; calcium supplements, average 600mg, were given to provide a total calcium intake of 1200 mg/d. The primary outcome was 12-month serum 25OHD level. Analysis methods include ANOVA and Pearson correlations. Results: The mean percent increase (±SD) in BMD at 12 months for all women was small; total body, 0.62% (± 2.72), femoral neck 0.59% (±3.58) and spine 0.43% (±2.80). There was no difference in BMD or serum N-telopeptide in response to vitamin D by dose or race. The increase in total body, spine and hip BMD in elderly women given vitamin D doses between 400 and 4800 IU daily and calcium supplementation is small, unrelated to dose or 12-month serum 25OHD, free 25OHD or 1,25(OH)2D. There was no evidence of a threshold change in BMD with increasing serum 25OHD or free 25OHD in this population. Conclusions: We found no significant effect of daily vitamin D dose ranging from 400 to 4800 IU/day on BMD or serum N-terminal telopeptides in elderly women with initially low serum 25OHD.

Original languageEnglish (US)
JournalJournal of Internal Medicine
DOIs
StateAccepted/In press - Jan 1 2018

Fingerprint

Vitamin D
Bone Density
Randomized Controlled Trials
Cholecalciferol
Serum
Calcium
Spine
Placebos
Pelvic Bones
collagen type I trimeric cross-linked peptide
Femur Neck
African Americans
Analysis of Variance
Population

All Science Journal Classification (ASJC) codes

  • Internal Medicine

Cite this

@article{209b452fcd284fc9ba4eb6c965b388f8,
title = "Effect of increasing doses of vitamin D on bone mineral density and serum N-terminal telopeptide in elderly women: a randomized controlled trial",
abstract = "Background: There are few controlled studies of the effect of different doses of vitamin D3 on bone mineral density (BMD). Objectives: We conducted a randomized placebo-controlled trial of increasing doses of vitamin D3 in 163 Caucasian and 31 African American women with serum 25-hydroxyvitamin D (25OHD) ≤50 nmol/L. This is an analysis of secondary outcome BMD to see if there is an association between percent change in BMD and dose of vitamin D3. Methods: Participants were randomly assigned to placebo, vitamin D3 400, 800, 1600, 2400, 3200, 4000, or 4800 IU/day; calcium supplements, average 600mg, were given to provide a total calcium intake of 1200 mg/d. The primary outcome was 12-month serum 25OHD level. Analysis methods include ANOVA and Pearson correlations. Results: The mean percent increase (±SD) in BMD at 12 months for all women was small; total body, 0.62{\%} (± 2.72), femoral neck 0.59{\%} (±3.58) and spine 0.43{\%} (±2.80). There was no difference in BMD or serum N-telopeptide in response to vitamin D by dose or race. The increase in total body, spine and hip BMD in elderly women given vitamin D doses between 400 and 4800 IU daily and calcium supplementation is small, unrelated to dose or 12-month serum 25OHD, free 25OHD or 1,25(OH)2D. There was no evidence of a threshold change in BMD with increasing serum 25OHD or free 25OHD in this population. Conclusions: We found no significant effect of daily vitamin D dose ranging from 400 to 4800 IU/day on BMD or serum N-terminal telopeptides in elderly women with initially low serum 25OHD.",
author = "Smith, {L. M.} and Gallagher, {John Christopher G.} and M. Kaufmann and G. Jones",
year = "2018",
month = "1",
day = "1",
doi = "10.1111/joim.12825",
language = "English (US)",
journal = "Journal of Internal Medicine",
issn = "0954-6820",
publisher = "Wiley-Blackwell",

}

TY - JOUR

T1 - Effect of increasing doses of vitamin D on bone mineral density and serum N-terminal telopeptide in elderly women

T2 - a randomized controlled trial

AU - Smith, L. M.

AU - Gallagher, John Christopher G.

AU - Kaufmann, M.

AU - Jones, G.

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Background: There are few controlled studies of the effect of different doses of vitamin D3 on bone mineral density (BMD). Objectives: We conducted a randomized placebo-controlled trial of increasing doses of vitamin D3 in 163 Caucasian and 31 African American women with serum 25-hydroxyvitamin D (25OHD) ≤50 nmol/L. This is an analysis of secondary outcome BMD to see if there is an association between percent change in BMD and dose of vitamin D3. Methods: Participants were randomly assigned to placebo, vitamin D3 400, 800, 1600, 2400, 3200, 4000, or 4800 IU/day; calcium supplements, average 600mg, were given to provide a total calcium intake of 1200 mg/d. The primary outcome was 12-month serum 25OHD level. Analysis methods include ANOVA and Pearson correlations. Results: The mean percent increase (±SD) in BMD at 12 months for all women was small; total body, 0.62% (± 2.72), femoral neck 0.59% (±3.58) and spine 0.43% (±2.80). There was no difference in BMD or serum N-telopeptide in response to vitamin D by dose or race. The increase in total body, spine and hip BMD in elderly women given vitamin D doses between 400 and 4800 IU daily and calcium supplementation is small, unrelated to dose or 12-month serum 25OHD, free 25OHD or 1,25(OH)2D. There was no evidence of a threshold change in BMD with increasing serum 25OHD or free 25OHD in this population. Conclusions: We found no significant effect of daily vitamin D dose ranging from 400 to 4800 IU/day on BMD or serum N-terminal telopeptides in elderly women with initially low serum 25OHD.

AB - Background: There are few controlled studies of the effect of different doses of vitamin D3 on bone mineral density (BMD). Objectives: We conducted a randomized placebo-controlled trial of increasing doses of vitamin D3 in 163 Caucasian and 31 African American women with serum 25-hydroxyvitamin D (25OHD) ≤50 nmol/L. This is an analysis of secondary outcome BMD to see if there is an association between percent change in BMD and dose of vitamin D3. Methods: Participants were randomly assigned to placebo, vitamin D3 400, 800, 1600, 2400, 3200, 4000, or 4800 IU/day; calcium supplements, average 600mg, were given to provide a total calcium intake of 1200 mg/d. The primary outcome was 12-month serum 25OHD level. Analysis methods include ANOVA and Pearson correlations. Results: The mean percent increase (±SD) in BMD at 12 months for all women was small; total body, 0.62% (± 2.72), femoral neck 0.59% (±3.58) and spine 0.43% (±2.80). There was no difference in BMD or serum N-telopeptide in response to vitamin D by dose or race. The increase in total body, spine and hip BMD in elderly women given vitamin D doses between 400 and 4800 IU daily and calcium supplementation is small, unrelated to dose or 12-month serum 25OHD, free 25OHD or 1,25(OH)2D. There was no evidence of a threshold change in BMD with increasing serum 25OHD or free 25OHD in this population. Conclusions: We found no significant effect of daily vitamin D dose ranging from 400 to 4800 IU/day on BMD or serum N-terminal telopeptides in elderly women with initially low serum 25OHD.

UR - http://www.scopus.com/inward/record.url?scp=85053544102&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85053544102&partnerID=8YFLogxK

U2 - 10.1111/joim.12825

DO - 10.1111/joim.12825

M3 - Article

JO - Journal of Internal Medicine

JF - Journal of Internal Medicine

SN - 0954-6820

ER -